ファーマコビジランス(市販後医薬品安全性監視)の世界市場:産業分析・機会分析

◆英語タイトル:Pharmacovigilance Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2020
◆商品コード:FMI609104
◆発行会社(調査会社):Future Market Insights
◆発行日:2015年12月4日
◆ページ数:151
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Individual (single user)USD5,000 ⇒換算¥570,000見積依頼/購入/質問フォーム
EnterpriseUSD10,000 ⇒換算¥1,140,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はFuture Market Insights社の日本における正規販売代理店です。Future Market Insights社の概要及び新刊レポートはこちらでご確認いただけます。



※本調査レポートでは、ファーマコビジランス(市販後医薬品安全性監視)の世界市場について調査・分析し、市場概観、ファーマコビジランス(市販後医薬品安全性監視)の世界市場規模、市場規模予測、地域別分析(アメリカ、ヨーロッパ、アジア等)、セグメント別市場分析、競争状況、ファーマコビジランス(市販後医薬品安全性監視)市場動向、関連企業分析などを含め、以下の構成でお届けいたします。
【レポートの概要】

Future Market Insights offers a 6-year forecast of the global pharmacovigilance market between 2015 and 2020. In terms of value, the market is expand at a CAGR of 14.2% during the forecast period. This study demonstrates market dynamics and trends in all seven regions that are expected to influence the current environment and future status of the pharmacovigilance market over the forecast period.
Report Description

This Future Market Insights report examines the pharmacovigilance market for the period 2015-2020. The primary objective of the report is to offer insights into developments in the pharmacovigilance market that are significantly transforming global businesses and enterprises.

The global pharmacovigilance market report begins by defining pharmacovigilance and its various segments. This is followed by an overview of the global pharmacovigilance market. The overview section includes FMI analysis of key trends, drivers, restraints, trends and opportunities that are influencing growth of the pharmacovigilance market currently. It also includes information related to the market shares of the major players in the market. Impact analyses of key growth drivers and restraints based on the weighted average model have been included in this report on the global pharmacovigilance market to better equip customers and readers with region specific trends and insights.

The primary driving factor for growth of the pharmacovigilance market is the significant increase witnessed in the intake of medical drugs. Besides, increase in prevalence of acute and chronic diseases has consequently led to an increase in incidences of drug consumption, thereby leading to a rise in the number of adverse drug events and drug toxicity cases. This, in turn, has triggered the growth of the pharmacovigilance market globally. Furthermore, safety regulations, risk of high-profile safety issues and need to review large volume of post-market events along with negative media coverage have compelled the pharmaceutical players to take support of various outsourcing services for drug monitoring. Factors such as intensifying regulatory expectations, tougher inspection system and instant need for patient reporting are boosting the adoption rate of pharmacovigilance among pharmaceutical companies globally. Pharmaceutical companies are now entering into long-term partnerships/service agreements with CROs and BPOs to reduce the pharmacovigilance process related expenditure, incurred right from drug discovery to post-marketing approvals.

The global pharmacovigilance market is segmented based on phase of drug development, type of reporting methods and type of service providers. On the basis of phase of drug development, the market has been segmented into preclinical studies, phase I clinical trial, phase II clinical trial, phase III clinical trial and phase IV clinical trial or post-marketing surveillance. On the basis of type of reporting methods, the market has been segmented into spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring and EHR mining. On the basis of the type of service providers, the market has been segmented into in-house and contract outsourcing. A detailed analysis has been provided for all segments and sub-segments in terms of market size, Y-o-Y growth rate, absolute $ opportunity and BPS analysis.

A deep market analysis along with market attractiveness index for each of the categories have been provided in the report. The next section of the report highlights the pharmacovigilance market by region. It provides a market outlook for 2015–2020 and sets the forecast within the context of the pharmacovigilance market. The study discusses key regional trends contributing to growth of the pharmacovigilance market worldwide, as well as analyses the extent to which the drivers are influencing this market in each region. Key regions assessed in this report include North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan and the Middle East & Africa.

The above sections, by phase of drug development, type of reporting methods and type of service providers and region, evaluate the present scenario and growth prospects of the pharmacovigilance market for the period 2015 –2020. We have considered 2014 as the base year and provided data for the forecast period, i.e. 2015–2020.

To ascertain the market size of pharmacovigilance, we have also considered revenue generated by pharmacovigilance companies. The forecast presented here assesses the total revenue generated across the pharmacovigilance market. In order to offer an accurate forecast, we started by sizing the current market, which forms the basis of how the pharmacovigilance market is expected to develop in the future. Given the characteristics of the market, we triangulated the outcome of three different types of analysis, based on supply side, downstream industry demand and the economic envelope.

In addition, it is imperative to note that in an ever-fluctuating global economy, we not only conduct forecasts in terms of CAGR, but also analyse the market based on key parameters, such as Year-on-Year (Y-o-Y) growth rates, to understand the predictability of the market and to identify the right growth opportunities in the market.

In this report, the pharmacovigilance market is segmented in terms of phase of drug development, type of reporting methods, type of service providers and region. These segments are analysed in terms of Basis Point Share (BPS) to understand individual segment’s relative contributions to market growth. This detailed level of information is important for identification of various key trends in the pharmacovigilance market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective of the pharmacovigilance market.

To understand key growth segments in terms of growth across the globe in the near future, Future Market Insights developed the pharmacovigilance market attractiveness index. The resulting index should help providers identify real market opportunities.

In the final section of the report, the ‘Competitive Landscape’ of the market is included to provide report audiences with a dashboard view, based on categories of providers in the value chain of the pharmacovigilance product portfolio and key differentiators. Key categories of providers covered in the report are pharmacovigilance companies. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment of the pharmacovigilance value chain and the potential players with respect to the same. Report audiences can gain segment-specific vendor insights to identify and evaluate key competitors based on their in-depth assessment of capabilities and successes in the pharmacovigilance marketplace.

Detailed profiles of the pharmacovigilance companies are also included in the scope of the report to evaluate their long-term and short-term strategies, key offerings, SWOT analysis and recent developments. Key players included in the report are Accenture plc, Bristol-Myers Squibb, Clinquest Group B.V., Cognizant Technology Solutions, Covance, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc (GSK), ICON plc, iGATE Corporation, iMEDGlobal Corporation, inVentiv Health, Inc., Novartis International AG, PAREXEL International Corporation, Pfizer, Inc., Pharmaceutical Product Development, LLC. (PPD), PRA Health Sciences, Inc., Quintiles Transnational Holdings, Inc., Sanofi S.A., Synowledge LLC and Wipro Limited.

Key Segments Covered

By Phases of Drug Development

Preclinical Studies
Phase I
Phase II
Phase III
Phase IV or Post Marketing Surveillance

By Type of Method

Spontaneous Reporting
Intensified ADR Reporting
Targeted Spontaneous Reporting
Cohort Event Monitoring
EHR Mining

By Type of Service Provider

In-house Pharmacovigilance
Contract Outsourcing

Key Regions/Countries Covered

North America
U.S.
Canada
Latin America
Brazil
Argentina
Mexico
Rest of Latin America
Western Europe
U.K.
France
Germany
Spain
Italy
Nordics
BENELUX
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific Excluding Japan (APEJ)
Greater China
India
ASEAN
Australia and New Zealand
Rest of APEJ
Japan
Middle East & Africa
GCC
South Africa
Rest of MEA

Key Companies

Accenture plc
Bristol-Myers Squibb
Clinquest Group B.V.
Cognizant Technology Solutions
Covance, Inc.
Hoffmann-La Roche Ltd.
GlaxoSmithKline plc (GSK)
ICON plc
iGATE Corporation
iMEDGlobal Corporation
inVentiv Health, Inc.
Novartis International AG
PAREXEL International Corporation
Pfizer, Inc.
Pharmaceutical Product Development, LLC. (PPD)
PRA Health Sciences, Inc.
Quintiles Transnational Holdings, Inc.
Sanofi A.
Synowledge LLC
Wipro Limited

【レポートの目次】

Table Of Content

1 Introduction

1.1 Report Description

1.2 Research Methodology

1.3 Market Segmentation

2 Executive Summary

3 Global Pharmacovigilance Market Dynamics

3.1 Introduction

3.2 Market Drivers

3.2.1 Increasing Consumption of Drugs Would Fuel Demand for Continuous Drug Event Monitoring

3.2.2 Rise in Cases of Adverse Drug Reactions and Drug Toxicity Would Boost Demand for Pharmacovigilance Activities

3.2.3 Rise in Adoption of Outsourcing Services Expected to Accentuate the Market Growth

3.3 Market Restraints

3.3.1 High Risk Associated with Data Security in Pharmacovigilance Outsourcing

3.3.2 Lack of Availability of Skilled Labour Might Hinder the Market Growth

3.3.3 Inadequate Pharmacovigilance System for Herbal Products in Asia Pacific Might Hamper the Market Growth

3.4 Market Opportunities

3.4.1 Huge Scope for Rapid Growth of Pharmacovigilance Market in Emerging Economies

3.4.2 Shift in Preference for Outsourcing among Various Pharmaceutical and Life Sciences Companies

3.5 Porter’s Five Forces Analysis: Global Pharmacovigilance Market

3.5.1 Bargaining Power of Suppliers

3.5.2 Bargaining Power of Buyers

3.5.3 Threat of Substitutes

3.5.4 Threat of New Entrants

3.5.5 Competitive Rivalry

3.6 Market Attractiveness Analysis: Global Pharmacovigilance Market, by Geography

3.7 Competitive Landscape

3.7.1 Market Share Analysis: Global Pharmacovigilance Market, 2014 (Value %)

4 Global Pharmacovigilance Market, by Phase of Drug Development

4.1 Overview

4.1.1 Global Pharmacovigilance Market Revenue, by Phase of Drug Development, 2014-2020 (US$ Mn)

4.1.2 Comparative Analysis: Global Pharmacovigilance Market Revenue, by Type of Clinical Trial Phases, 2014(Value %)

4.2 Preclinical Studies

4.2.1 Global Preclinical Studies Pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

4.3 Phase I

4.3.1 Global Phase I Clinical Trial Pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

4.4 Phase II

4.4.1 Global Phase II Clinical Trial Pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

4.5 Phase III

4.5.1 Global Phase III Clinical Trial Pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

4.6 Phase IV or Post Marketing Surveillance

4.6.1 Global Phase IV Clinical Trial Pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

5 Global Pharmacovigilance Market, By Type of Methods

5.1 Overview

5.1.1 Global Pharmacovigilance Market Revenue, by Type of Method , 2014-2020 (US$ Mn)

5.2 Comparative Analysis: Global Pharmacovigilance Market Revenue, by Type of Method, 2014(Value %)

5.3 Spontaneous Reporting

5.3.1 Global Spontaneous Reporting Market Revenue, 2014-2020 (US$ Mn)

5.4 Intensified ADR Reporting

5.4.1 Global Intensified ADR Reporting Market Revenue, 2014-2020 (US$ Mn)

5.5 Targeted Spontaneous Reporting

5.5.1 Global Targeted Spontaneous Reporting Market Revenue, 2014-2020 (US$ Mn)

5.6 Cohort Event Monitoring

5.6.1 Global Cohort Event Monitoring Market Revenue, 2014-2020 (US$ Mn)

5.7 EHR Mining

5.7.1 Global EHR Mining Market Revenue, 2014-2020 (US$ Mn)

6 Global Pharmacovigilance Market, by Type Service Provider

6.1 Overview

6.1.1 Global Pharmacovigilance Market Revenue, by Type of Service Provider, 2014-2020 (US$ Mn)

6.1.2 Comparative Analysis: Global Pharmacovigilance Market, by Type of Service Providers, 2014 (Value %)

6.2 In-house Pharmacovigilance

6.2.1 Global In-House Pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

6.3 Contract Outsourcing

6.3.1 Global Contract Outsourcing Pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

7 Global Pharmacovigilance Market, by Geography

7.1 Overview

7.1.1 Global Pharmacovigilance Market Revenue, by Geography, 2014-2020 (US$ Mn)

7.2 North America

7.2.1 North America Pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

7.3 Europe

7.3.1 Europe Pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

7.4 Asia Pacific

7.4.1 Asia Pacific Pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

7.5 Rest of the World (RoW)

7.5.1 RoW pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

8 Recommendations

8.1 Market Strategy

8.1.1 Strategic Partnerships and Collaborations With CROs And Life Sciences BPOs

8.1.2 Optimization of Drug Safety Through Hub and Spoke Model

8.1.3 Developing Operational Activities for Better Outcomes

8.1.4 Regional Expansion

9 Company Profiles

9.1 Accenture plc

9.2 Bristol-Myers Squibb

9.3 Clinquest Group B.V.

9.4 Cognizant Technology Solutions

9.5 Covance, Inc.

9.6 F. Hoffmann-La Roche Ltd.

9.7 GlaxoSmithKline plc (GSK)

9.8 ICON plc

9.9 iGATE Corporation

9.10 iMEDGlobal Corporation

9.11 inVentiv Health, Inc.

9.12 Novartis International AG

9.13 PAREXEL International Corporation

9.14 Pfizer, Inc.

9.15 Pharmaceutical Product Development, LLC. (PPD)

9.16 PRA Health Sciences, Inc.

9.17 Quintiles Transnational Holdings, Inc.

9.18 Sanofi S.A.

9.19 Synowledge LLC

9.20 Wipro Limited
List of Tables

TABLE 1 : Market Snapshot: Pharmacovigilance Market

TABLE 2 : Global Pharmacovigilance Market Revenue, by Phases of Drug Development, 2014-2020 (US$ Mn)

TABLE 3 : Global Pharmacovigilance Market Revenue, by Type of Method, 2014-2020 (US$ Mn)

TABLE 4: Global Pharmacovigilance Market Revenue, by Type of Service Provider, 2014-2020 (US$ Mn)

TABLE 5 : Global Pharmacovigilance Market Revenue, by Geography, 2014-2020 (US$ Mn)
List of Figures

FIG. 1: Drug Safety from Molecule to Market

FIG. 2: Pharmacovigilance: Market Segmentation

FIG. 3: Global Pharmacovigilance Market, by Phase of Drug Development, 2014 (US$ Mn)

FIG. 4: Global Pharmacovigilance Market, by Type of Service Provider, 2014 (US$ Mn)

FIG. 5: Global Pharmacovigilance Market, by Type of Method, 2014 (US$ Mn)

FIG. 6: Comparative Analysis: Global Pharmacovigilance Market, by Geography, 2014 (Value %)

FIG. 7: Porter’s Five Forces Analysis: Global Pharmacovigilance Market

FIG. 8: Market Attractiveness Analysis: Global Pharmacovigilance Market, by Geography (2014)

FIG. 9: Global Pharmacovigilance Market Share Analysis, by Key Player, 2014(%)

FIG. 10: Safety Services: Product Lifecycle

FIG. 11: Comparative Analysis: Global Pharmacovigilance Market Revenue, by Phase of Drug Development, 2014(Value %)

FIG. 12: Global Preclinical Studies Pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

FIG. 13: Global Phase I Clinical Trial Pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

FIG. 14: Global Phase II Clinical Trial Pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

FIG. 15: Global Phase III Clinical Trial Pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

FIG. 16: Global Phase IV Clinical Trial Pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

FIG. 17: Comparison of Methods: Pharmacovigilance reporting

FIG. 18: Comparative Analysis: Global Pharmacovigilance Market Revenue, by Type of Method, 2014 & 2020 (Value %)

FIG. 19: Global Spontaneous Reporting Market Revenue, 2014-2020 (US$ Mn)

FIG. 20: Global Intensified ADR Reporting Market Revenue, 2014-2020 (US$ Mn)

FIG. 21: Global Targeted Spontaneous Reporting Market Revenue, 2014-2020 (US$ Mn)

FIG. 22: Global Cohort Event Monitoring Market Revenue, 2014-2020 (US$ Mn)

FIG. 23: Global EHR Mining Market Revenue, 2014-2020 (US$ Mn)

FIG. 24: End-to-End Safety Across the Lifecycle

FIG. 25: Comparative Analysis: Global Pharmacovigilance Market, by Type of Service Provider, 2014 & 2020 (Value %)

FIG. 26: Global In-House Pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

FIG. 27: Global Contract Outsourcing Pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

FIG. 28: North America Pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

FIG. 29: Europe Pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

FIG. 30: Asia Pacific Pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

FIG. 31: RoW Pharmacovigilance Market Revenue, 2014-2020 (US$ Mn)

FIG. 32: Accenture, Plc.: Annual Revenue 2014 (US$ Bn)

FIG. 33: Bristol-Myers Squibb: Annual Revenue, 2014 (US$ Mn)

FIG. 34: Cognizant Technology Solutions: Annual Revenue, 2014 (US$ Mn)

FIG. 35: COVANCE, Inc.: Annual Revenue, 2014 (US$ Mn)

FIG. 36: F. Hoffmann-La Roche Ltd., Annual Revenue: 2014 (US$ Mn)

FIG. 37: GlaxoSmithKline plc (GSK): Annual Revenue, 2014(US$ Mn)

FIG. 38: ICON plc: Annual Revenue, 2014 (US$ Mn)

FIG. 39 iGATE Corporation: Annual Revenue, 2014 (US$ Mn)

FIG. 40: Novartis International AG: Annual Revenue, 2014 (US$ Mn)

FIG. 41: PAREXEL International Corporation: Annual Revenue 2014 (US$ Mn)

FIG. 42: Pfizer, Inc.: Annual Revenue, 2014 (US$ Mn)

FIG. 43: PRA Health Sciences, Inc., Annual Revenue: 2014 (US$ Mn)

FIG. 44: Quintiles Transnational Holdings, Inc.: Annual Revenue, 2014 (US$ Mn)

FIG. 45: Sanofi: Annual Revenue, 2014 (US$ Mn)

FIG. 46: Wipro Limited: Annual Revenue 2014 (US$ Mn)



【レポートのキーワード】

ファーマコビジランス、市販後医薬品安全性監視

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[ファーマコビジランス(市販後医薬品安全性監視)の世界市場:産業分析・機会分析]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月02日現在 219,162 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆